Switching to long-acting injectable (LAI) antipsychotics may help people with schizophrenia stay employed. A large Taiwanese cohort study found that adults who transitioned to LAI treatment showed modestly better employment trends over time compared to those on oral antipsychotics — suggesting treatment type, not just diagnosis, shapes work outcomes.
People diagnosed with schizophrenia face steep employment challenges — but the type of treatment they receive may make a real difference. A nationwide cohort study using Taiwan's National Health Insurance Research Database found that working-age adults with schizophrenia had dramatically lower employment rates than matched peers without the diagnosis (33.9% vs. 66.2%), with job losses beginning even before the official diagnosis.
The good news? Transitioning to long-acting injectable (LAI) antipsychotics was associated with a modestly more favorable employment trajectory compared to staying on oral antipsychotics — even though LAI users started with lower baseline employment rates. The benefit was most pronounced among adults aged 30–44, those early in their illness (1–3 years), and those with poor medication adherence at baseline.
By the Numbers:
Why it matters: Employment is a key marker of recovery and quality of life. This study suggests that clinicians who switch patients to LAI therapy — particularly those with adherence challenges — may be supporting not just symptom control, but also long-term functional outcomes like holding a job.
